- 专利标题: Engineered monomeric antibody fragments
-
申请号: US14650188申请日: 2013-11-25
-
公开(公告)号: US10233229B2公开(公告)日: 2019-03-19
- 发明人: Tetsuya Ishino , Weili Duan , Ronald William Kriz
- 申请人: Pfizer Inc.
- 申请人地址: US NY New York
- 专利权人: Pfizer Inc.
- 当前专利权人: Pfizer Inc.
- 当前专利权人地址: US NY New York
- 国际申请: PCT/IB2013/060384 WO 20131125
- 国际公布: WO2014/087299 WO 20140612
- 主分类号: C07K1/00
- IPC分类号: C07K1/00 ; C07K16/00 ; C12P21/08 ; C07H21/04 ; C12P21/06 ; C12P21/04 ; C12N5/00
摘要:
The present invention relates to monomeric polypeptides comprising an engineered monomeric antibody fragment (e.g., monomeric Fc-containing polypeptides) wherein the monomeric Fc comprises one or more engineered N-linked glycosylation sites in the CH3-CH3 dimerization interface. Methods for producing such engineered monomeric antibody fragments and their use in diagnostics and therapeutics are also provided.
公开/授权文献
- US20150322135A1 ENGINEERED MONOMERIC ANTIBODY FRAGMENTS 公开/授权日:2015-11-12
信息查询